Pfizer’s (PFE) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Pfizer (NYSE:PFE) in a research note published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $45.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on the company. Argus lowered Pfizer from a buy rating to a hold rating in a research report on Friday, March 22nd. Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the stock an equal weight rating in a research report on Thursday, May 2nd. Finally, BMO Capital Markets reaffirmed an outperform rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $35.54.

Pfizer Stock Performance

Shares of PFE opened at $27.98 on Wednesday. The business’s fifty day moving average price is $27.90 and its 200 day moving average price is $27.68. Pfizer has a 12-month low of $25.20 and a 12-month high of $37.80. The stock has a market capitalization of $158.55 billion, a PE ratio of -466.26, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the business posted $1.23 earnings per share. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts forecast that Pfizer will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 6.00%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Ironvine Capital Partners LLC boosted its position in shares of Pfizer by 2.1% in the 1st quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 353 shares during the period. Advisor OS LLC boosted its position in shares of Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC boosted its position in shares of Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares during the period. Lantz Financial LLC boosted its position in shares of Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 381 shares during the period. Finally, Wellington Shields Capital Management LLC boosted its position in shares of Pfizer by 1.3% in the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 385 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.